FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
Dr. Eliot Richard Forster M.B.A., Ph.D.
Healthcare
Biotechnology
NASDAQ
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-s...
0001566373
US30315R1077
30315R107
Eddeva B920
44 1223 497400
GB
84
May 6, 2016
0001566373
NASDAQ
Biotechnology
Healthcare
30315R107
US30315R1077
GB
7.12
-0.35
747.28k
156.51M
-
2.07-7.12
0
-
-
-
-
-3.89
-
https://www.f-star.com
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Seeking Alpha
Jan 28, 2023
FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.
Seeking Alpha
Jul 29, 2022
F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.
Zacks Investment Research
Jul 15, 2022
GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.
Zacks Investment Research
Jun 24, 2022
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Benzinga
Jun 23, 2022
invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million.
Zacks Investment Research
May 10, 2022
Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
May 3, 2022
Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Alpha
Mar 14, 2022
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript